New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
19:47 EDTABTFDA advisory committee votes 5-3 in favor of Abbott's MitraClip benefits
Abbott announced that the U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted Yes: 5, No: 3 that the benefits of treatment with the MitraClip device outweigh its risks in patients with significant symptomatic mitral regurgitation who have been determined by a cardiac surgeon to be too high risk for open mitral valve surgery and in whom existing co-morbidities would not preclude the expected benefit from correction of the MR. On the separate question of whether there is reasonable assurance the device is safe, the panel voted Yes: 8, No: 0. On the question of whether there is reasonable assurance of efficacy, the panel voted Yes: 4, No: 5. The FDA will take into account the panel's advice in making its decision on whether to approve the MitraClip for the treatment of significant MR in the United States. The company expects a decision later this year.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
11:33 EDTABTAward of $16M to Sanofi, Abbott for damages upheld on appeal
The Court of Appeals for the Federal Circuit affirmed a lower court ruling that Glenmark Pharmaceuticals infringed a patent related to the antihypertension drug Tarka that is owned by or exclusively licensed to Sanofi (SNY), Abbott Labs (ABT), and their related companies. In the prior case, Glenmark admitted infringement and the jury awarded $15.2M in lost profits and about $800K in price erosion damages. The appeals court affirmed the district court's jurisdiction in the matter, as well as its judgment and related rulings. Reference Link
April 16, 2014
13:54 EDTABTDanone slips after fresh dairy volume shrinks
Subscribe for More Information
09:35 EDTABTAbbott: We have plenty of cash for M&A activity, not constrained on borrowing
09:15 EDTABTAbbott sees pace of EPS growth and sales to accelerate throughout FY14
Subscribe for More Information
09:14 EDTABTAbbott sees Q2 EPS 50c-52c, consensus 51c
Sees Q2 sales growth in low to mid single digits, consensus $5.54B.
09:13 EDTABTAbbott sees accelerating sales growth in 2H14
Subscribe for More Information
07:49 EDTABTAbbott expects to increase global capacity to meet demand in 2014
Expects three new manufacturing facilities scheduled to come on line in China, India and the U.S. in Q2. Adult Nutrition remains on track to achieve an operating margin ratio of more than 20 percent of sales by 2015.
07:47 EDTABTAbbott completes enrollment in U.S., China, Japan in Absorb regulatory trials
Subscribe for More Information
07:46 EDTABTAbbott backs FY14 adjusted EPS $2.16-$2.26, consensus $2.20
07:46 EDTABTAbbott reports Q1 adjusted EPS 41c, consensus 36c
Subscribe for More Information
April 15, 2014
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:14 EDTABTEarnings Preview: Abbott's established pharmaceuticals sales in focus
Subscribe for More Information
April 14, 2014
09:05 EDTABTAbbott announces FDA clearance for test to diagnose diabetes
Subscribe for More Information
April 10, 2014
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use